CB1 antagonists are provided. Such compounds may be used to modulate CB1
activity in vivo or in vitro, and are particularly useful in the
treatment of conditions responsive to CB1 receptor modulation in humans,
domesticated companion animals and livestock animals, including appetite
disorders, obesity and addictive disorders. Pharmaceutical compositions
and methods for using them to treat such disorders are provided, as are
methods for using ligands for receptor localization studies and various
in vitro assays.